(CercleFinance.com) – Alcon, the world leader in eye care, rose on the stock market on Wednesday after results just in line with market expectations and a downward revision of its annual objectives.
The Swiss specialist in ophthalmology, a former subsidiary of Novartis, reported yesterday evening a turnover of 2.1 billion dollars for the third quarter, up 2% on a reported basis and 9 % at constant exchange rates.
The Geneva-based group, which offers products against cataracts, glaucoma or retinal diseases, posted basic earnings per share (EPS) of $0.50, compared to $0.54 in the third quarter of the year. fiscal year 2021.
For comparison, analysts were targeting revenue of $2.15 billion for core EPS of $0.50.
Alcon, which says its results reflect an “extremely difficult” economic environment, has lowered its revenue estimate for this year, citing the strong dollar.
While he previously predicted net sales between $8.6 billion and $8.8 billion for 2022, his new forecast shows a range between $8.5 billion and $8.7 billion.
‘It should be noted, however, that at constant exchange rates, the group now expects sales growth of between 10% and 11%, which is above the range of 7% to 9% that it aimed at the beginning of the year’, point out the analysts of UBS.
Consequently, the Alcon title listed on the Zurich Stock Exchange rose by 2% on Wednesday morning following this publication.
Copyright (c) 2022 CercleFinance.com. All rights reserved.